Oxford Biomedica Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	53.88	60.65	103.72	141.29	108.94	46.74
Trading Asset Securities	-	-	-	-	0.07	0.24
Cash & Short-Term Investments	53.88	60.65	103.72	141.29	109.02	46.98
Cash Growth	-33.82%	-41.52%	-26.59%	29.60%	132.04%	147.77%
Accounts Receivable	45.54	41.33	13.34	45.01	35.95	47.33
Other Receivables	11.53	13.7	7.04	12.61	6.15	4.1
Receivables	57.07	55.03	20.39	57.62	42.1	51.42
Inventory	15.6	13.57	12.87	12.63	9.52	6.91
Prepaid Expenses	5.23	3.94	4.36	3.98	3.21	2.63
Total Current Assets	131.77	133.19	141.33	215.5	163.84	107.95
Property, Plant & Equipment	55.33	64.3	75.69	133.78	69.73	72.3
Goodwill	-	-	-	0.66	-	-
Other Intangible Assets	24.32	29.22	30.98	105.23	0.05	0.07
Long-Term Accounts Receivable	0	0.03	0.04	-	-	-
Other Long-Term Assets	4.9	4.9	4.3	5.01	3.61	3.61
Total Assets	216.32	231.64	252.34	460.18	237.23	183.93
Accounts Payable	10.02	9.61	6.05	13.6	5.26	7.78
Accrued Expenses	10.48	15.04	10.27	20.63	11.9	10.35
Current Portion of Long-Term Debt	-	0.28	-	-	-	-
Current Portion of Leases	4.62	4.14	3.65	3.3	0.85	4.48
Current Income Taxes Payable	1.76	1.51	1.48	2.35	1.9	1.59
Current Unearned Revenue	41.76	24.19	22.11	19.26	13.4	28.26
Other Current Liabilities	1.05	3.54	0.75	-	-	-
Total Current Liabilities	69.7	58.32	44.32	59.66	33.31	52.46
Long-Term Debt	36.81	39.79	38.53	39.78	-	-
Long-Term Leases	63.99	64.55	69.27	71.21	8.49	9.37
Long-Term Unearned Revenue	5.67	1.07	5.33	1.15	1.85	3.52
Long-Term Deferred Tax Liabilities	-	-	-	5.59	-	-
Other Long-Term Liabilities	7.42	7.42	17.06	46.61	6.24	5.84
Total Liabilities	183.59	171.16	174.51	223.99	49.89	71.18
Common Stock	53.07	52.98	48.4	48.13	43.09	41.16
Additional Paid-In Capital	394.86	394.86	380.33	379.95	307.77	258.02
Retained Earnings	-420.89	-399.5	-352.92	-198.55	-165.81	-188.72
Comprehensive Income & Other	5.68	8.71	-1.81	-24.89	2.29	2.29
Total Common Equity	32.73	57.05	74.01	204.65	187.34	112.75
Minority Interest	-	3.44	3.83	31.54	-	-
Shareholders' Equity	32.73	60.49	77.83	236.19	187.34	112.75
Total Liabilities & Equity	216.32	231.64	252.34	460.18	237.23	183.93
Total Debt	105.42	108.76	111.46	114.28	9.34	13.85
Net Cash (Debt)	-51.55	-48.11	-7.74	27	99.68	33.14
Net Cash Growth	-	-	-	-72.91%	200.80%	213.41%
Net Cash Per Share	-0.50	-0.47	-0.08	0.28	1.16	0.41
Filing Date Shares Outstanding	106.14	105.96	96.8	96.26	86.18	82.32
Total Common Shares Outstanding	106.14	105.96	96.8	96.26	86.18	82.32
Working Capital	62.07	74.87	97.01	155.84	130.54	55.49
Book Value Per Share	0.31	0.54	0.76	2.13	2.17	1.37
Tangible Book Value	8.41	27.83	43.03	98.77	187.29	112.67
Tangible Book Value Per Share	0.08	0.26	0.44	1.03	2.17	1.37
Machinery	68.29	70.8	65.33	61.02	40.17	33.71
Leasehold Improvements	58.94	61.29	61.06	60.23	28.15	27.22
Order Backlog	-	150	94	94	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.